“Latest Stem Cells News”

The use of human embryos for therapeutic or diagnostic purposes which are applied to the human embryo and are useful to it is patentable, but their use for purposes of scientific research is not patentable

Mr Oliver Brüstle is the holder of a patent, filed on 19 December 1997, which concerns isolated and purified neural precursor1 cells produced from human embryonic stem cells used to treat neurological diseases. According to the information supplied by Mr Brüstle, there are already clinical applications, particularly for patients suffering from Parkinson’s disease.

On application by Greenpeace e.V., the Bundespatentgericht (Federal Patent Court, Germany) ruled that Mr Brüstle’s patent was invalid in so far as it covers processes for obtaining precursor cells from human embryonic stem cells.
The Bundesgerichtshof (Federal Court of Justice, Germany), hearing Mr Brüstle’s appeal, decided to refer questions to the Court of Justice concerning the interpretation of, in particular, the concept of ‘human embryo’ which is not defined in Directive 98/44/EC on the legal protection of biotechnological inventions2.

Incoming search terms:

Scientists have taken the first steps toward producing the “heart patch,” a design for a medical implement used to repair damage from heart disease, a new study suggests.

Last week, researchers from Duke University presented the results of a study which, using mouse embryonic stem cells, examined the way these cells develop into heart muscle, HealthDay News reports (…)

from http://www.privatemdlabs.com/news/Heart_Health_and_Cholesterol/Mouse-stem-cell-study-examines-heart-repair$19405309.php

Incoming search terms:

An international team of scientists led by researchers at The Scripps Research Institute has developed a straightforward technique to determine the ethnic origin of stem cells.

The team’s analysis of a variety of human embryonic stem cell lines currently in use in research laboratories around the world found that these cells originated largely from Caucasian and East Asian populations, with little representation from populations originating in Africa. In response to these results, the scientists used skin cells from an individual of West African Yoruba heritage to create a new stem cell line, the first to carry the genetic profile of this ethnic group.

Incoming search terms:

Five years after the passage of Proposition 71, the California Institute of Regenerative Medicine is awarding grants for stem-cell research targeted at clinical applications. In what both the San Diego Union-Tribune and Knight Science Journalism Tracker are calling an “irony,” ten of the 14 grants are going to researchers working with adult stem-cells.

On Thursday, October 29, the New York Times reported: “In a tacit acknowledgment that the promise of human embryonic stem cells is still far in the future, California’s stem cell research program on Wednesday awarded grants intended to develop therapies using mainly other, less controversial cells.

“The $230 million in grants awarded Wednesday to California universities and companies represent a big step toward moving stem cells from basic research toward application in treating diseases like cancer and AIDS. Grant recipients are supposed to have a therapy ready for initial human testing in four years.

“But only four of the 14 projects involve embryonic stem cells. The others will use so-called adult stem cells or conventional drugs intended to kill cancer stem cells, which are thought to give rise to tumors.

“The grants thus represent a departure from the program’s original mission. California voters approved the 10-year, $3 billion effort in 2004 largely to get around restrictions on embryonic stem cell research imposed by the administration of President George W. Bush.”

Incoming search terms:

Researchers from A*STAR Singapore took lead roles in a study that identified a portion of the genome mutated during long-term culture of human embryonic stem cells (hESCs). The study was a worldwide collaboration, led by Drs Peter Andrews of the University of Sheffield (UK), Paul Robson of the Genome Institute of Singapore (GIS), Steve Oh of Singapore’s Bioprocessing Technology Institute (BTI), and Barbara Knowles and others in the international stem cell community. The GIS, IMB and BTI are research institutes under the umbrella of the Agency for Science, Technology and Research, (A*STAR), Singapore.

Involving 125 ethnically diverse hESC lines originating from 38 laboratories globally, and now identified to represent multiple ethnic groups from different parts of the globe, the study is the largest to be conducted on the genetic stability of cultured hESCs. The findings are published today in the journal Nature Biotechnology.

Research into the variability of hESCs is very important as these cells may lead to future cell therapy and regenerative medicine. During long-term culture, however, these cells can acquire genetic changes (mutations), some of which could compromise the cells’ utility for regenerative medicine. It is believed that mutations that arise and endure over long-term culture provide a selective advantage for the cells, such as a greater propensity for self renewal.

Incoming search terms:

The U.S. government approved the first 13 batches of human embryonic stem cells on Wednesday, enabling researchers using them to get millions of dollars in federal funding as promised by President Barack Obama in March.

“Today we are announcing the approval of the first 13 stem cell lines,” Collins told reporters in a telephone briefing.

In March, Obama lifted restrictions on human embryonic stem cell research imposed by his predecessor, George W. Bush.

He could not lift a restriction set by Congress, called the Dickey-Wicker amendment, that forbids the use of federal money to make the stem cells, which require destruction of a human embryo. But the decision made it possible for researchers to use federal funds to work with cells that others have made.

Incoming search terms: